{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sanmamed MF"],"funding":["National Cancer Institute","NCI NIH HHS","National Institutes of Health"],"pagination":["1988-1995"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5834104"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(8)"],"pubmed_abstract":["<h4>Background</h4>Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients.<h4>Patients and methods</h4>Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of "],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients."],"pmcid":["PMC5834104"],"funding_grant_id":["P50 CA121974","SAF2011-22831","SAF2014-52361-R"],"pubmed_authors":["Morgado M","Chen L","Sznol M","Melero I","Perez-Gracia JL","Andueza MP","Wang J","Alfaro C","Martin-Algarra S","Bacchiocchi A","Schalper KA","Kluger H","Rodriguez-Ruiz ME","Fusco JP","Onate C","Halaban R","Sanmamed MF","Perez G","Gonzalez A","Gurpide A"],"additional_accession":[]},"is_claimable":false,"name":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.","description":"<h4>Background</h4>Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes in serum IL-8 levels as a biomarker of response to anti-PD-1 blockade in melanoma and non-small-cell lung cancer (NSCLC) patients.<h4>Patients and methods</h4>Metastatic melanoma and NSCLC patients treated with nivolumab or pembrolizumab alone or nivolumab plus ipilimumab were studied. Serum was collected at baseline; at 2-4 weeks after the first dose; and at the time-points of response evaluation. Serum IL-8 levels were determined by sandwich ELISA. Changes in serum IL-8 levels were compared with the Wilcoxon test and their strength of association with response was assessed with the Mann-Whitney test. Accuracy of ","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Aug","modification":"2025-04-19T15:18:08.534Z","creation":"2019-03-26T23:48:52Z"},"accession":"S-EPMC5834104","cross_references":{"pubmed":["28595336"],"doi":["10.1093/annonc/mdx190"]}}